[Phase III study of bestatin in patients with malignant skin tumors. (1) Malignant melanoma].
As a co-operative study involving 18 medical research institutions, we have made a randomized, controlled study (phase III study) of Bestatin in the treatment of malignant melanoma (stage Ib, II) over the last 4 years. The results were as follows; Bestatin significantly prolonged disease-free intervals by 9-20 month. Bestatin significantly prolonged survival periods by 10-16 months. Side effects of Bestatin, chiefly comprising of reversible gastro-intestinal disturbances, were observed in 7.1% of Bestatin-treated cases. These findings suggest that Bestatin is a very useful agent for treating for stage Ib and II malignant melanomas.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008197:Lymph Node Excision; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D011379:Prognosis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000903:Antibiotics, Antineoplastic; D007930:Leucine; C012211:ubenimex